Kathleen Slattery-Moschkau is a prominent individual, whose involvement in a trifecta of groundbreaking films has had a profound effect on the general public's comprehension of the intricate relationships between corporate entities and the medical profession.
The inaugural cinematic endeavor, "Side Effects", made its debut in the year 2005, unfolding as a thought-provoking and intellectually stimulating exploration of the pharmaceutical industry's profound influence on the medical landscape, serving as a poignant commentary on the intricate relationship between the two entities and the far-reaching consequences that arise from their symbiotic bond.
In the year 2006, a significant turning point occurred when Slattery-Moschkau, a visionary individual, chose to shine a spotlight on the pressing and deeply concerning issue of profit-driven healthcare, which had been quietly plaguing the system for some time. This decision led to the creation of a powerful documentary film, titled "Money Talks: Profits Before Patient Safety", which aimed to bring attention to a reality that was often overlooked and underappreciated by the general public. The documentary effectively highlighted the alarming truth that, all too frequently, the relentless pursuit of financial gain could and often did take precedence over the well-being and safety of patients.
Notably, Slattery-Moschkau's most recent documentary endeavour, aptly titled "Making a Killing: The Untold Story of Psychotropic Drugging", emerged onto the scene in 2008, thereby shedding light on a realm of psychotropic medications that had hitherto remained largely unexplored.
Within the realm of this thought-provoking documentary, the filmmaker delved into the complex and often contentious practices and protocols surrounding the utilization of these medications, thereby presenting a powerful exposé that served to illuminate the intricacies of this oft-misunderstood domain.
Through this film, Slattery-Moschkau provided a platform for the dissemination of crucial information, thereby contributing to a greater understanding of the multifaceted issues surrounding psychotropic medications and their widespread use.
